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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYChemical biologymethods such as high-throughput screening (HTS) and affinity-based target identification can be used to probe biolog-
ical systems on a biomacromolecule level, providing valuable insights into the molecular mechanisms of those systems. Here, by estab-
lishing a human embryonal carcinoma cell-based HTS platform, we screened 171,077 small molecules for regulators of pluripotency and
identified a smallmolecule, Displurigen, that potently disrupts hESC pluripotency by targeting heat shock 70-kDa protein 8 (HSPA8), the
constitutively expressed member of the 70-kDa heat shock protein family, as elucidated using affinity-based target identification tech-
niques and confirmed by loss-of-function and gain-of-function assays. We demonstrated that HSPA8maintains pluripotency by binding
to the master pluripotency regulator OCT4 and facilitating its DNA-binding activity.INTRODUCTION
The pluripotency regulators OCT4, NANOG, and SOX2
form a core transcription regulatory network through
auto- and reciprocal activations at the transcription level,
which is believed to be responsible for the maintenance
of human embryonic stem cell (hESC) pluripotency (Boyer
et al., 2005). At the same time, multiple protein factors
belonging to a diversity of functional categories, such as
transcription factors, epigenetic factors, and signaling
components, work cooperatively to form an expanded
pluripotency factor network that supports the core plurip-
otency network (Boyer et al., 2005). In contrast to the
well-defined core network, our knowledge of this expanded
pluripotency network, including its components, the inter-
actions between these components, and themechanism of
interaction between the expanded network and the core
network, remains insufficient.
Bioactive small molecules have been applied to the field
of hESC research with success. Many such studies have
applied small molecules as modulators of lineage-specific
differentiations (Borowiak et al., 2009; Chen et al., 2009,
2012; Gonzalez et al., 2011a; Lian et al., 2012; Mahmood
et al., 2010). Other studies have exploited small molecules
as chemical probes to uncover novel molecular mecha-
nisms underlying hESC pluripotency or differentiation
(Chen et al., 2006; Xu et al., 2010; Zhu et al., 2009).
High-throughput screenings (HTS) were usually conducted
for the search of such molecules. If the mechanism of ac-
tion was unknown for a given molecule, affinity-based
target identification methods can be used to identify
its biological target(s). These studies have been used toStem Cell Repidentify novel protein factors and to unveil previously
unknown molecular mechanisms that regulate hESC fate
determination (Xu et al., 2008).
In recent years, hESCs and human induced pluripotent
stem cells (hiPSCs) have been used successfully for HTS in
several studies (Barbaric et al., 2010; Ben-David et al.,
2013; Desbordes et al., 2008; Gonzalez et al., 2011b; Ka-
meoka et al., 2014; Kumagai et al., 2013; Manganelli et al.,
2014; Xu et al., 2010). However, the high cost associated
with the maintenance and scale-up of human pluripotent
stem cells (hPSCs) inevitably limits the scale of their appli-
cation in HTS studies. We chose to explore an alternative
source of pluripotent stem cells, human embryonal carci-
noma cells (hECCs), as a robust platform for HTS with low
cost. hECCs are pluripotent stem cells derived from human
teratocarcinomas and are considered to be the malignant
counterparts of hESCs. The molecular regulatory mecha-
nism of hECC pluripotency has been shown to mimic
that of hESCs (Josephson et al., 2007). Because of their
cancerous nature, hECCs are not prone to spontaneous dif-
ferentiation and require a less demanding culture condition
compared with hPSCs. Experimental results acquired from
studies using hECCs have been proven to be highly stable
and readily reproducible (Josephson et al., 2007), making
hECCs ideal candidate platforms for HTS purposes.
Based on the concept of hECC-based HTS, we established
a pluripotency reporter system using the hECC line
NTERA-2. Using this system, we conducted a large-scale
chemical screening and found 122 small molecules that
disrupt hESC pluripotency. One of these molecules, which
we named Displurigen, potently disrupts hESC pluripo-
tency by targeting heat shock 70-kDa protein 8 (HSPA8,orts j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 The Authors 1143
the constitutively expressed member of the 70-kDa heat
shock protein family), as discovered using affinity-based
target identification methods and functional validations.
We demonstrated that HSPA8 helps maintain pluripotency
by direct binding to the OCT4 protein and facilitating
OCT4 binding to DNA.RESULTS
Establishment of an NTERA-2 Cell-Based Pluripotency
Reporter System
To avoid high experimental variations associated with
hESC-basedHTS platforms, we established anHTS platform
using the hECC line NTERA-2. NTERA-2 is a clonal subline
of TERA-2, one of the first established hECC lines (Andrews
et al., 1984). NTERA-2 cells are able to differentiate into all
three germ layers in vivo in the form of teratocarcinomas.
In culture, these cells differentiate in response to several in-
ducers of differentiation, most notably retinoic acid (RA)
(Andrews, 1984), hexamethylene bis-acetamide (HMBA)
(Andrews et al., 1986, 1990), and bonemorphogenetic pro-
tein 7 (Andrews et al., 1994). These agents also induce dif-
ferentiation of hESCs (Draper et al., 2002; Xu et al., 2002;
zur Nieden et al., 2005). Furthermore, basic fibroblast
growth factor (bFGF) helps maintain the pluripotent state
of both NTERA-2 cells and hESCs (Andrews et al., 1984;
Thomson et al., 1998). The similarities in their responses
toward external factors indicate that NTERA-2 cells and
hESCs have very similar molecular mechanisms governing
their respective pluripotent states.
An NTERA-2 cell-based reporter cell line was constructed
by stable integration of an EGFP reporter gene driven by a
4-kb OCT4 promoter (Gerrard et al., 2005). EGFP-positive
cells were selected by flow cytometry after drug selection.
The selected stable cell line nearly homogeneously ex-
pressed EGFP andmaintained this expression aftermultiple
(more than 20) rounds of passaging (Figure 1A). This re-
porter line is hereafter referred to as NTERA-2-OP4k, with
‘‘OP4k’’ referring to the 4-kb OCT4 promoter. To test the
response of this reporter system to known external regula-
tors of pluripotency, NTERA-2-OP4k cells were cultured at
low density and incubatedwith known inhibitors of plurip-
otency, including RA and HMBA, and with an enhancer of
pluripotency, bFGF, for 6–7 days. The Rho-associated coiled
coil-containing protein kinase (ROCK) inhibitor Y-27632
was also tested as a cell survival enhancer (Watanabe et al.,
2007). RA and HMBA dramatically reduced the cellular
EGFP signal, as shown by fluorescence-activated cell sorting
(FACS) analysis and fluorescent imaging (Figure 1B; Fig-
ure S1A). This was accompanied by a dramatic downregu-
lation of the endogenous protein expression of OCT4,
as shown by western blotting (Figure S1B). On the other1144 Stem Cell Reports j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 Thhand, in bFGF- and Y-27632-treated cells, EGFP expression
and the endogenous expression of OCT4 remained largely
unaltered comparedwith theDMSO control (Figure 1B; Fig-
ure S1). These results demonstrate that the EGFP expression
of NTERA-2-OP4k reporter cells is regulated by known regu-
lators of pluripotency in the same way as the expression of
endogenous OCT4 and indicate that the OCT4-EGFP re-
porter signal faithfully reflects the endogenous expression
of OCT4 and the pluripotency state of the cells.
NTERA-2-OP4k Cell-Based HTS Identified Small
Molecule Regulators of Pluripotency
Before applying theNTERA-2-OP4k reporter system toHTS,
we first verified whether the responses of the OCT4-EGFP
reporter could be accurately measured under HTS condi-
tions. For this test, NTERA2-OP4k cells were seeded at low
densities (0.1–0.25 3 105 cells/cm2) in 96-well plates. Plu-
ripotency and survival regulators, including RA, HMBA,
bFGF, and Y-27632, were added immediately following
cell plating. Cells were incubated for 6–7 days without me-
dium change and then scanned for EGFP signals using a
fluorescence plate reader. As a result, cells treated with the
pluripotency inhibitors RA and HMBA showed signifi-
cantly decreased EGFP signals, whereas bFGF- and
Y-27632-treated cells maintained high levels of EGFP sig-
nals compared with the DMSO control (Figure 1C). This
result is consistent with the results obtained previously
by FACS analysis and fluorescence imaging in non-HTS set-
tings (Figure 1B; Figure S1A), confirming the validity of us-
ing NTERA-2-OP4k as a pluripotency reporter line for HTS.
For HTS, 171,077 small molecules with diverse chemical
structures were screened using the NTERA-2-OP4k reporter
cell-based platform. These molecules were hosted by the
University of Illinois at Urbana-Champaign (UIUC) HTS
facility in four chemical libraries. For the screen, NTERA-
2-OP4k cells were seeded at low densities in 96- or 384-
well plates and incubated with screening compounds and
DMSO controls (included in all screening plates), added
using pin tools immediately after seeding, at the final con-
centrations described in the Supplemental Experimental
Procedures. Cells were kept in a 37C incubator for
6–7 days without medium change and then scanned for
EGFP signal intensities using a fluorescence plate reader.
Wells with EGFP intensities lower than 70% of the average
EGFP intensity of the DMSO controls (average level of
background signals subtracted before comparison) in the
same plates were identified as candidate hits.
We expect two types of compounds to produce false pos-
itives by reducing EGFP signal intensities in the treated
wells without inducing cellular differentiation. These
include cytotoxic or apoptosis-inducing compounds that
caused cell death (Figure 1D, Cell Death) and compounds
that inhibited cell proliferation (Figure 1D, Reducede Authors
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Figure 1. Establishment of an NTERA-2-OP4k Reporter Cell-Based HTS System and General Outcome of the Screen
(A) Fluorescent (top) and phase contrast (bottom) images of NTERA-2-OP4k cells. Scale bar, 100 mm.
(B) Histogram of GFP expression in NTERA-2-OP4k cells analyzed by flow cytometry. Cells were treated with DMSO, Y-27632 (10 mM), bFGF
(4 ng/ml), RA (10 mM), and HMBA (3 mM) for 6 days.
(C) Quantification of GFP intensity after treatment of NTERA-2-OP4k cells with DMSO, Y-27632, bFGF, RA, and HMBA for 6 days. Cells were
cultured in the 96-well plate format. GFP intensity was determined using an Analyst HT fluorescence plate reader. Each bar represents
mean ± SD (error bars). n = 4 independent experiments. *p < 0.05, as determined by Student’s t test.
(D) Schematic (top) of several cellular outcomes of NTERA-2-OP4k cells after the chemical screening. Representative fluorescent (center)
and phase-contrast (bottom) images were taken from the actual screening and are shown for each outcome. Scale bar, 100 mm.
(E) Number of total compounds screened and hit compounds identified after each step of screening. The hit rates (in parentheses) were
calculated based on the ratio of hit compounds and total compounds. Compounds from four different libraries (Marvel, NCI, house, and
ChemBridge library) were screened. Because of the large number of compounds hosted by the libraries (171,077 compounds total), only
one round of screening (n = 1) was performed for the entire compound collection.
See also Figure S1.growth). A compound that fell into either of the two cate-
gories would have reduced the total number of cells in the
treated well and, therefore, been able to lower its EGFP
signal intensity without actually disrupting the pluripotent
status of cells in that well. A real hit compound, however,
would have downregulated EGFP expression on a cellular
level (Figure 1D, Primary hits). To distinguish between
the actual hit compounds and compounds that generated
false positive signals, we inspected all wells that showed
significant EGFP signal reduction under a fluorescence mi-
croscope immediately after the fluorescence plate reader
scan. Based on the criteria described above and shown in
Figure 1D, we identified the wells in which EGFP signalsStem Cell Repwere reduced on a cellular level as true primary hits. As a
result, although 2,865 compounds (1.7% of all compounds
screened) were identified as candidate hits based on their
reduced EGFP signals, only 214 of those compounds
(0.13%of all compounds screened) were verified as primary
hits (Figure 1E).
We then validated the pluripotency disruption activities
of the primary hits in hESCs. Primary hit compounds were
cherry-picked from the original screening plates and
applied to hESCs at concentrations close to the concentra-
tions used in the HTS (Supplemental Experimental Proce-
dures). H1 and H9 hESCs were seeded as colonies and incu-
bated with the compounds under the feeder-independentorts j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 The Authors 1145
pluripotency culture condition (Experimental Procedures)
for 4–6 days. The medium was changed, and the com-
pounds were replenished every day or every other day. Cul-
tures were monitored every day for loss of compact colony
morphologies as signs of differentiation. Compounds that
failed to disrupt hESC colony integrity at the concentra-
tions tested were examined again at 5- to 10-fold increased
concentrations under the same condition. Finally, 122
compounds were found to disrupt hESC colony integrity
(Figure 1E). These compounds are hereafter referred to as
hESC-verified hits or verified hits.
From the verified hits, we selected the ones that showed
strong potencies (effective at relatively low concentra-
tions) at inducing hESC differentiation, acquired those
compounds in bulk from commercial sources, and further
verified their activities at the molecular level. Various
techniques, including western blotting, qPCR, immuno-
staining, and FACS analysis, were used to examine
changes in the expression of pluripotency markers upon
treatment of those compounds. Of the more than 30
compounds tested in detail, 29 compounds efficiently
downregulated the expression of pluripotency markers
in H1 and H9 hESCs (data not shown).
The Compound Displurigen Potently Disrupts hESC
Pluripotency
Of those 29 compounds, compound NSC375009 from the
National Cancer Institute (NCI) library was one of themost
potent. We hereafter refer to this compound as Displurigen
(Displg for short) for its property as a ‘‘reagent that disrupts
pluripotency’’ (Figure 2A).When applied at 5 mMfor 6 days,
the colony integrity of hESCs was completely disrupted,
as evidenced by cells within the colonies spread out and
migrated away from each other (Figure 2B). Protein levels
of OCT4 and NANOG were also downregulated after
6 days of 5 mM Displg treatment, but SOX2 expression
stayed roughly unchanged during this period (Figure S2A).
FACS analysis under the same treatment condition also
showed that, although the majority of cells lost OCT4
and NANOG expression on day 6, approximately 25% of
the cells remainedOCT4+NANOG+ (Figure S2B), indicating
that roughly 25% of the population remained pluripotent
even after 6 days of Displg treatment at 5 mM.
To achieve amore robust differentiation, we testedDisplg
at higher concentrations. We found that a 10 mM concen-
tration was sufficient for Displg to nearly completely anni-
hilate the OCT4+NANOG+ population (from 88.29% to
0.67%; Figure 2C) after only 4 days of treatment. Western
blotting showed similar results at the protein level (Fig-
ure 2D). Both FACS analysis and western blotting results
showed that protein levels of the pluripotency markers
OCT4, NANOG, and SOX2 remained largely unchanged af-
ter 24 hr of 10 mMDisplg treatment (Figures 2C and 2D). In1146 Stem Cell Reports j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 Thcontrast, qPCR results indicated that the mRNA levels of
OCT4 and NANOG decreased significantly after 24 hr of
10 mM Displg treatment and continued to decrease during
the remaining course of differentiation (Figure 2E). These
results showed that, upon Displg treatment, the changes
of pluripotency marker expression at the mRNA level pre-
ceded those at the protein level, indicating that the pri-
mary regulatory pathway affected by Displg may be related
to the regulation of mRNA. To rule out the possibility that
Displg did not directly disrupt pluripotency but, rather, en-
riched differentiated or differentiating cells in the culture
by selectively killing or inhibiting cell-cycle progression
of pluripotent hESCs, we conducted apoptosis and cell-cy-
cle analyses for 2-day and 4-day 10 mMDisplg-treated cells.
Apoptosis analysis using Annexin V and propidium iodide
(PI) showed less than 5% apoptosis rates (Annexin V+ pop-
ulations) in samples treated with 10 mM Displg for 2 and
4 days, which were only mild elevations compared with
DMSO controls (Figure S2C). Cell-cycle analysis using PI
staining also showed that cell-cycle progression was not
affected by 10 mM Displg treatment after 2 and 4 days. In
fact, the percentages of G2/M phase cells even mildly
increased in Displg-treated cells compared with DMSO
controls (Figure S2D), possibly because of compensation
effects against the increased cell deaths in Displg treatment
samples (Figure S2C).
We then examined whether Displg induced epithelial-
mesenchymal transition (EMT) and lineage-specific differ-
entiation of hESCs. The epithelial marker E-cadherin and
the mesenchymal markers N-cadherin and Fibronectin 1
(FN1) were examined in samples treated with 10 mMDisplg
for 1–4 days. E-cadherin mRNA expression was reduced
significantly starting from day 2 and persisted through
day 4, whereas N-cadherin and FN1 expression was consis-
tently upregulated starting on day 2 and day 1, respectively
(Figure 2F). To examine whether Displg induces lineage-
specific differentiation, multiple lineage-specific marker
genes (eight neuroectoderm markers, ten mesoderm
markers, eight endodermmarkers, and two trophectoderm
markers) were selected and analyzed in H1 and H9 hESCs
subjected to 6 days of differentiation under a basal differen-
tiation medium (Supplemental Experimental Procedures)
usingqPCR.Three independent experimentswere conduct-
ed. The overall average expression of eachmarker gene, pre-
sented as the relative level compared with DMSO control,
was organized and is shown as heatmaps in Figure 2G (H1
hESC) and Figure S2E (H9hESC). RA andHMBAwere exam-
ined inparallelwithDisplg. Interestingly, althoughbothRA
and HMBA enhanced the expression of multiple lineage
markers of various lineages, Displg inhibited the elevation
of almost all differentiation markers examined, compared
with DMSO controls, in both H1 and H9 hESCs (Figure 2G;
Figure S2E). These data demonstrated that, apart frome Authors
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Figure 2. Compound NSC375009 (Displurigen) Disrupts hESC Pluripotency
(A) Chemical structure of compound NSC375009 (Displg).
(B) Phase-contrast images of H9 hESCs treated with DMSO and Displg (5 mM) for 2 days. Scale bar, 100 mm.
(C) Intracellular FACS analysis of OCT4A and NANOG in H1 hESCs left untreated (mTeSR1) or treated with 10 mM Displg for 1–4 days.
(D) Western blotting of OCT4, SOX2, and NANOG in H1 hESCs left untreated (mTeSR1) or treated with 10 mM Displg for 1–4 days (d).
a-Tubulin was used as a loading control.
(E) qPCR analysis of OCT4 and NANOG in H1 hESCs left untreated (mTeSR1) or treated with 10 mM Displg for 0.5–4 days. All values were
normalized to the level (= 1) of mRNA in cells without compound treatment. Each bar represents mean ± SD (error bars). n = 3 independent
experiments. *p < 0.05, **p < 0.01, as determined by Student’s t test. ACTB (b-actin) was used as a loading control.
(F) qPCR analysis of epithelial (E-cadherin) and mesenchymal (N-cadherin, FN1) markers in H1 hESCs treated with 10 mM Displg for 1–4 days.
All values were normalized to the level (= 1) of mRNA in cells without compound treatment. Each bar represents mean ± SD (error bars).
n = 3 independent experiments. *p < 0.05, ***p < 0.001, as determined by Student’s t test. ACTB (b-actin) was used as a loading control.
(G) Heatmap showing qPCR analysis of neuroectoderm (NE), mesoderm (MESO), endoderm (ENDO), and trophectoderm (TE) markers in H1
hESCs treated with Displg (10 mM), RA (10 mM), and HMBA (3 mM) for 6 days under differentiation conditions. All values were normalized to
the level (= 1) of mRNA in the DMSO control. Each bar represents mean ± SD (error bars). The overall average value of relative mRNA
expression from three independent experiments is shown. ACTB (b-actin) was used as a loading control.
See also Figure S2.disrupting pluripotency, Displg also inhibited lineage-
specific differentiation, indicating that the target of Displg
may not only be required for maintaining pluripotency
but also needed for supporting the proper lineage-selective
differentiation of hESCs.
Displg Disrupts hESC Pluripotency by Targeting
HSPA8
To identify the biological target of Displg, we synthesized a
biotinylated version of the compound by linking a linker
and a biotin molecule at the -OH site of Displg (Figure 3A).Stem Cell RepThis molecule is hereafter referred to as Displg-biotin.
Displg-biotin disrupted hESC pluripotency, as shown by
loss of colony integrity and downregulation of OCT4 (Fig-
ures 3B and 3C), although at a higher dosage (50 mM)
compared with unmodified Displg. This result indicates
that Displg-biotin reserves the bioactivity of its parent
compound Displg, although with a weaker potency. The
decrease in potency of Displg-biotin may be due to the
larger size of the molecule preventing its cellular uptake.
Using Displg-biotin as a probe, we conducted an affinity-
based pull-down experiment (Experimental Procedures).orts j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 The Authors 1147
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Figure 3. Displurigen Targets HSPA8
(A) Chemical structure of Displg-biotin.
(B) Phase-contrast images of H1 hESCs treated with DMSO and Displg-biotin (100 mM) for 4 days. Scale bar, 100 mm.
(C) Western blotting of OCT4 in H1 hESCs treated with DMSO, Displg (10 mM), and Displg-biotin (100 mM) for 6 days. a-Tubulin was used as a
loading control.
(D) Silver staining of SDS-PAGE gel with proteins pulled down by Displg-biotin. DMSO was used as a control. Mass spectrometry analysis
revealed HSPA8 protein as a target of Displg-biotin.
(E) Western blotting of OCT4 and HSPA8 isoform 1 in undifferentiated H1 hESCs versus H1 hESCs subjected to EB differentiation for 10 days.
a-Tubulin was used as a loading control.
(F) Western blotting of HSPA8 isoform 1 in the precipitates of Displg-biotin (10 mM) and DMSO pull-down assays using H9 hESC lysates.
Total lysates used were normalized between the DMSO and Displg-biotin pull-down assays.
(G) In vitro ATPase activity of HSP70 in the presence of increasing doses of Displurigen (n = 1 independent experiment).
See also Figure S3.Briefly, hESCs treatedwithDisplg-biotin or aDMSOcontrol
were lysed and then incubated with streptavidin beads.
Proteins bound to Displg-biotin were eluted and analyzed
using SDS-PAGE followed by silver staining. A distinct
band was consistently observed in the Displg-biotin pull-
down samples, but not in the control samples, at approxi-
mately 70 kDa and was identified to be HSPA8 (also known
as HSC70) by mass spectrometry analysis with a score
above the significance threshold (p < 0.05) (Figure 3D; Fig-
ure S3A). Three protein hits of human origin were identi-
fied in this analysis and are listed in Figure S3A. Two keratin
proteins were identified but excluded from being consid-
ered as potential hits because keratins are known to be
common contaminants of mass spectrometry (Lavalle´e-
Adam et al., 2011). Seven unique trypsin-digested peptide
fragments were identified for HSPA8, Their respective posi-
tions within the protein sequence are shown in Figure S3B.
HSPA8 is the constitutively expressed member of the 70-
kDa heat shock protein family, as opposed to the stress-
induced HSP70. Two previous publications (Fathi et al.,
2009; Son et al., 2005) show that HSPA8 is expressed in un-1148 Stem Cell Reports j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 Thdifferentiated hESCs but downregulated upon differentia-
tion. In our hands, however, 4 days of Displg treatment
at 10 mMwere not enough to downregulate HSPA8 expres-
sion at the protein level (Figure S3C). We argue that, as a
constitutively expressed heat shock protein that is vital to
the routine functioning of the cells, the expression of
HSPA8 may have been maintained by multiple pathways
simultaneously and may not be easily downregulated
within 4 days of differentiation. Indeed, our data showed
that HSPA8 was dramatically downregulated after 10 days
of embryoid body (EB) differentiation (Figure 3E; Supple-
mental Experimental Procedures), revealing a link between
HSPA8 expression and hESC pluripotency. We therefore
hypothesized that HSPA8 may be the biological target of
Displg.
To test this hypothesis, we first confirmed the interac-
tion between Displg and HSPA8 by applying the pull-
down samples to western blotting, which showed that
Displg indeed bound to and pulled down HSPA8 (Fig-
ure 3F). We also performed an in vitro ATPase assay using
recombinant HSP70, which is structurally highly similar toe Authors
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Figure 4. HSPA8 is the Biological Target of Displurigen.
(A) Phase-contrast images of H9 hESCs infected with lentivirus particles containing non-target (NT) shRNA or shRNAs (shRNA1 and
shRNA2; Supplemental Experimental Procedures) targeting HSPA8 isoform 1 for 5 days. Scale bar, 100 mm.
(B) Western blotting of HSPA8 isoform 1, OCT4, SOX2, and NANOG in H1 hESCs infected with lentivirus particles containing NT shRNA and
HSPA8-1-targeting shRNAs. A lane showing OCT4 shRNA knockdown (KD) as a positive control was cropped (shown as gaps) from the
HSPA8, OCT4, and a-tubulin strips. The uncropped image is shown in Figure S4. a-Tubulin was used as a loading control.
(C) Intracellular FACS analysis of OCT4A and NANOG in H1 hESCs treated with DMSO, 10 mM Displurigen, 20 mM Apoptozole, and 20 mM
VER155008 for 4 days.
(D) Western blotting of HSPA8 isoform 1 and OCT4 in H1 hESCs treated with 10 mM Displg for 6 days with or without HSPA8 overexpression.
a-Tubulin was used as a loading control.
(E) Western blotting of HSP70, OCT4, SOX2, and NANOG in H9 hESCs treated with 5 mM Displg for 16 days with or without overexpression of
HSP70-AAAA. a-Tubulin was used as a loading control.
See also Figure S4.HSPA8 (Stricher et al., 2013), and showed that Displg in-
hibited the ATPase activity of HSP70 with a half-maximal
inhibitory concentration (IC50) of 225 mM (Figure 3G). We
then conducted loss-of-function experiments to examine
whether HSPA8 was the true biological target of Displg
in regard to its activity in disrupting pluripotency. Knock-
down of HSPA8 in hESCs using short hairpin RNAs
(shRNAs) disrupted pluripotency, as shown by loss of col-
ony integrity (Figure 4A) and downregulation of the plu-
ripotency markers OCT4, NANOG, and SOX2 (Figure 4B;
Figure S4 shows the uncropped blot). Other commercially
available HSP70/HSPA8 inhibitors, including Apoptozole
(Cho et al., 2011) (20 mM) and VER155008 (Massey
et al., 2010) (20 mM) also disrupted hESC pluripotency,
although less potently compared with Displg (Figure 4C).
These results demonstrate that HSPA8 is likely to be theStem Cell Repbiological target of Displg responsible for maintaining
hESC pluripotency.
To further verify HSPA8 as the primary target of Displg in
pluripotencymaintenance, we attempted to rescue the plu-
ripotency disruption effect of Displg by overexpressing
HSPA8 in hESCs. We first overexpressed wild-type HSPA8
protein, which rescued the effect of Displg, as shown by
the elevated OCT4 expression (Figure 4D). The efficiency
of this rescue was modest, which may be attributed to the
fact that overexpression of wild-type chaperone proteins
has been known to be harmful to cells (Freeman et al.,
1995). To achieve a more robust rescue, we overexpressed
a chaperone-dead mutant form of HSP70 protein, named
HSP70-AAAA (Freeman et al., 1995), in which the last
four amino acids were mutated from EEVD to AAAA.
Indeed, overexpression of HSP70-AAAA gave rise to aorts j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 The Authors 1149
more robust rescue of Displg, as demonstrated by the plu-
ripotency marker expressions (Figure 4E). These results
confirmed HSPA8 as the biological target of Displg and
further verified the function of HSPA8 in pluripotency
maintenance.
HSPA8 Maintains Pluripotency by Facilitating the
DNA-Binding Activity of OCT4
Heat shock proteins, as molecular chaperones, are involved
in a variety of cellular processes, including maintenance of
protein stability (Wegele et al., 2004), mediating the assem-
bly and disassembly of protein complexes (Ellis, 2007), and
the more recently discovered role of regulating the dy-
namics of protein-DNA association events such as tran-
scription (Freeman and Yamamoto, 2002; Mu¨ller et al.,
2004; Shaknovich et al., 1992; Stavreva et al., 2004; Waler-
ych et al., 2004). Our data showed that the downregulation
of core pluripotency factors at themRNA level preceded the
downregulation of those factors at the protein level (Fig-
ures 2C–2E). Specifically, mRNA levels of the pluripotency
factors were downregulated within the first 24 hr of Displg
treatment (Figure 2E), whereas their protein levels re-
mained largely unchanged after 24 hr of treatment (Figures
2C and 2D). This distinct dynamic indicated that HSPA8
most likely regulated the core pluripotency network at
the mRNA level. We therefore focused our efforts on inves-
tigating the role of HSPA8 in regulating the transcription of
the core pluripotency factors.
As discussed in the Introduction, the core pluripotency
regulators OCT4, NANOG, and SOX2 form a core transcrip-
tion regulatory network through auto- and reciprocal acti-
vations at the transcription level. This core network is
supported by an expanded network composed of a large
number of protein factors belonging to distinct functional
categories. We hypothesized that HSPA8 belongs to this
expanded network of protein factors andmaintains plurip-
otency through interacting with the core pluripotency fac-
tors and facilitating their transcription-activation activities
(Freeman and Yamamoto, 2002; Mu¨ller et al., 2004; Sha-
knovich et al., 1992; Stavreva et al., 2004; Walerych et al.,
2004). A nuclear fractionation assay demonstrated that
HSPA8 proteins are indeed present in the nuclei of undiffer-
entiated hESCs (Figure S5A), confirming the validity of our
hypothesis. For simplicity, we focused our study on exam-
ining the interaction between HSPA8 and the master
pluripotency regulator OCT4. Indeed, co-immunoprecipi-
tation (coIP) experiments showed that HSPA8 bound to
OCT4 and that this interaction was disrupted by Displg
(Figure 5A).
To test our hypothesis, we examined whether HSPA8 was
required for OCT4 protein to efficiently bind to DNA. We
first tested this potential regulatory mechanism using
electrophoretic mobility shift assay (EMSA) and discovered1150 Stem Cell Reports j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 Ththat Displg effectively reduced the binding affinities of
OCT4 to its DNA-binding motifs located in the OCT4,
NANOG, and SOX2 promoters (Catena et al., 2004; Chew
et al., 2005; Rodda et al., 2005; Figure 5B). Two distinct
bands (A and B; Figure 5B) were detected in EMSA. A super-
shift assay using anti-OCT4 antibody was conducted that
showed band A as the band representing OCT4 binding
to the DNA probes (Figure S5B). Three independent exper-
iments demonstrated that this inhibitory effect of Displg
was consistent and robust (Figure 5C) and indicated that
the activity of HSPA8 was necessary for OCT4 protein to
efficiently bind to DNA. We then examined whether this
regulatory effect depends on the presence of other protein
factors by conducting an in vitro binding assay using re-
combinant OCT4 and HSP70 proteins. OCT4 alone only
exhibited a weak binding affinity to DNA, whereas the
addition of 1–10 mM recombinant HSP70 dramatically
enhanced the OCT4-DNA interaction (Figure 5D).Without
OCT4, 10 mM HSP70 alone did not exhibit any detectable
DNA binding activity (Figure S5C; Figure S5D shows the
uncropped blot). Notably, 1 mM HSP70 protein was suffi-
cient to efficiently boost the DNA binding activity of
OCT4 from 100% in the OCT4-only control to an average
of 213% ± 26% (p < 0.01), based on the quantification of
band intensities from three independent experiments us-
ing ImageJ. Because the combined cellular concentration
of the constitutively expressed and stress-induced forms
of 70-kDa heat shock proteins under normal physiological
conditions is approximately 24 mM (Ghaemmaghami et al.,
2003; Jorgensen et al., 2007), the 1-mM concentration of
HSP70 tested in this experiment is well within its physio-
logical range and should not cause unwanted experimental
artifacts. This result suggests thatHSPA8 facilitates the asso-
ciation of OCT4-DNA complexes in a direct fashion inde-
pendent of other protein factors.DISCUSSION
In this study, we established an NTERA-2 hECC-based plu-
ripotency reporter system and screened 171,077 com-
pounds. We identified 29 bioactive small molecules that
potently disrupted hESC pluripotency, as evidenced by
changes in pluripotency marker expressions, and studied
one particularmolecule, Displurigen, in detail. Using target
identification techniques and functional verifications, we
discovered HSPA8 as the biological target of Displurigen.
HTS has been used for the discovery of novel small mole-
cule compounds that regulate PSC fate. Such studies
require the use of pluripotent cell lines as screening plat-
forms. Commonly available pluripotent platforms include
mouse and human ESCs, mouse and human ECCs, and the
more recently established mouse and human iPSCs. Thee Authors
A B D
C
Figure 5. HSPA8 Regulates the DNA-Binding Activity of OCT4
(A) Immunoprecipitation (IP) of OCT4 from H1 hESC lysates treated with DMSO or Displg (1 mM), followed by western blotting of OCT4 and
HSPA8 isoform 1.
(B) EMSA using labeled OCT4-binding elements from the OCT4, SOX2, and NANOG promoters to detect bindings of protein factors in the
nuclear extracts of H9 hESCs with or without Displurigen treatment (10 mM, 24 hr). A and B denote potential DNA-protein complexes, with
band A being the band representing OCT4-binding to the DNA probes (see also Figure S5B).
(C) Quantification of relative band intensities from three independent EMSA experiments using ImageJ. All values were normalized to the
level (= 1) of band intensity in the DMSO control. Each bar represents mean ± SD (error bars). **p < 0.01, as determined by Student’s t test.
(D) EMSA showing binding (arrow) of purified recombinant OCT4 proteins (500 ng/reaction) to a labeled OCT4-binding element in vitro
with or without the addition of purified recombinant HSP70 proteins (up to 10 mM).
See also Figure S5.earliest attempts of pluripotency regulator screenings
adopted mouse embryonic stem cells (mESCs) and mouse
embryonal carcinoma cells (mECCs) as their screening
platforms (Chen et al., 2006; Ding et al., 2003; Zhu et al.,
2009). More recently, several hESC- and hiPSC-based
HTSs have been reported (Barbaric et al., 2010; Ben-David
et al., 2013; Desbordes et al., 2008; Gonzalez et al.,
2011b; Kameoka et al., 2014; Kumagai et al., 2013; Manga-
nelli et al., 2014; Xu et al., 2010). Compared with those
platforms, we believe that hECCs have been underappreci-
ated for HTS. hECCs are cheap and easy to passage and
maintain, are robust in maintaining a pluripotent state
and not prone to spontaneous differentiation, and are of
human origin and highly similar to hESCs in their molecu-
lar regulatorymechanismof pluripotency (Josephson et al.,
2007). These qualities collectively make hECCs an ideal
system for HTS purposes, but, to date, to our knowledge,
only one attempt has been made to use hECCs for a HTS
study in which 80 chemical compounds were screened
(Barbaric et al., 2011). In comparison, our hECC-based
HTS platform was used to successfully screen a significant
number (171,077) of chemical compounds in this study.
Heat shock proteins, as molecular chaperones, are
involved in a variety of cellular functions. Apart from theirStem Cell Repcommonly known roles in maintaining protein stability
and mediating the assembly and disassembly of protein
complexes, recent studies have shown that certain chaper-
ones, including HSPA8, also regulate the dynamic forma-
tion of protein-DNA complexes involved in biological pro-
cesses such as transcription, telomere maintenance, DNA
repair, and DNA replication (Ahn et al., 2005; DeZwaan
and Freeman, 2010). Although a previous report has
demonstrated a regulatory role of the chaperone protein
Hsp90 in maintaining mESC pluripotency through inter-
acting with the core pluripotency factors (Bradley et al.,
2012), the possible role of chaperones in directly regulating
the DNA-binding and, subsequently, the transcription-
activation activities of the core pluripotency factors has
yet to be investigated. Our study examined this potential
molecularmechanism and unveiled a function of the chap-
erone protein HSPA8 inmaintaining hESC pluripotency by
directly facilitating the transcription-activation activity of
the master pluripotency factor OCT4.
Our study also adds anotherHSPA8/HSP70 inhibitor, Dis-
plurigen, to the current reservoir of bioactive small mole-
cules. The modulation of heat shock protein activities has
been studied extensively for potential clinical applications
such as cancer therapy. In contrast to normal cells, cancerorts j Vol. 5 j 1143–1154 j December 8, 2015 j ª2015 The Authors 1151
cells strongly overexpress HSP70 to provide resistance to
stresses generated by the environment, from tumorigenesis
events, and during cancer therapy. This addiction to HSP70
provides the theoretical basis for its targeting in anti-cancer
treatment (Goloudina et al., 2012; Jego et al., 2013). In
recent years, several HSPA8/HSP70 inhibitors have been
discovered and studied for their applications in anti-cancer
therapies (Goloudina et al., 2012). The discovery of Dis-
plurigen expands this growing list of HSPA8/HSP70 inhib-
itors and provides a drug candidate for cancer therapy.
In summary, by establishing and applying a hECC-based
HTS system, our study identifies a chemical inhibitor of
HSPA8/HSP70 and unveils a chaperone-related molecular
mechanism for the maintenance of hESC pluripotency.EXPERIMENTAL PROCEDURES
Generation and Validation of NTERA-2-OP4k Reporter
Cells
The plasmid containing EGFP driven by a fragment of the OCT4
promoter (4 kb) was provided by Dr. Wei Cui (Imperial College
London) and was as described previously (Gerrard et al., 2005).
NTERA-2-OP4k cells were established and validated as described
in the Supplemental Experimental Procedures.
Large-Scale Chemical Screening
Large-scale chemical screening was conducted at the High-
Throughput Screening Facility (HTSF) at the University of Illinois
at Urbana-Champaign (http://www.scs.illinois.edu/htsf/index.
html). The HTSF hosts 171,077 compounds from several com-
pound libraries, including the Marvel Library, the HTSF house li-
brary, the ChemBridge MicroFormat library, and the NCI library.
Because of the large number of compounds hosted by the libraries,
only one round of screening (n = 1) was performed for the entire
compound collection. Detailed procedures of this screen are
described in the Supplemental Experimental Procedures.
Affinity Chromatography, Electrophoresis, and Silver
Staining
hESCswere cultured under the feeder-independent conditionwith
or without the presence of displurigen-biotin (10 mM) overnight.
Cells were collected and subjected to affinity chromatography,
electrophoresis, and silver staining as described in the Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.09.023.
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